Studies to understand and exploit 10-membered enediyne biosynthesis
Project Number1R01CA217255-01A1
Former Number1R01GM121060-01A1
Contact PI/Project LeaderTHORSON, JON SCOTT Other PIs
Awardee OrganizationUNIVERSITY OF KENTUCKY
Description
Abstract Text
ABSTRACT
The 10-membered enediynes [exemplified by calicheamicin (CLM), esperamicin (ESP) and dynemicins (DYN)]
are arguably among the most renowned natural products (NPs) discovered to date by virtue of their
unprecedented complex molecular architectures, notable anticancer and anti-infective potencies and, in the case
of CLM, demonstrated clinical utility. The current study builds on a longstanding collaborative effort of
achievement and discovery relating to key aspects of 10-membered enediyne biosynthesis as well as parallel
innovative efforts to co-opt key biosynthetic catalysts for synthetic applications. The studies put forth will take
advantage of this strong foundation and a powerful combination of genetic, biochemical, chemical and protein
structural tools to elucidate the remaining unusual biosynthetic transformations and to exploit select catalysts for
enediyne non-native modification. Specifically, aims 1 and 2 will focus on extending our understanding of the
fundamental steps of enediyne core biosynthesis common to CLM/DYN/ESP, DYN anthraquinone biosynthesis
and a selected set of unique tailoring reactions (CLM/ESP thiosugar sulfur installation and aminopentose N-
alkylation, ESP C6-hydroxylation and O-glycosylation). In parallel, aim 3 will focus on tactical structural studies
to augment both aims 1 and 2 and the structural study of ‘unknowns’ to facilitate functional annotation. Additional
studies in aim 2 with key catalysts and corresponding non-native substrates are designed to assess the potential
for strategic installation of chemoselective handles to enable novel approaches for facile, mild bioconjugation of
CLM to tumor-targeting mAbs (in collaboration with Pfizer).
Public Health Relevance Statement
PROJECT NARRATIVE
This proposal seeks to study a prioritized set of highly unique enzyme-catalyzed transformations involved in
the biosynthesis of antitumor natural products (10-membered enediynes) and develop new strategies to
conjugate 10-membered enediynes to tumor-targeting agents. The proposed studies will advance our
fundamental understanding of natural product biosynthesis and provide strategies for enhancing the clinical
utility of enediynes in the treatment of cancer.
No Sub Projects information available for 1R01CA217255-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01CA217255-01A1
Patents
No Patents information available for 1R01CA217255-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01CA217255-01A1
Clinical Studies
No Clinical Studies information available for 1R01CA217255-01A1
News and More
Related News Releases
No news release information available for 1R01CA217255-01A1
History
No Historical information available for 1R01CA217255-01A1
Similar Projects
No Similar Projects information available for 1R01CA217255-01A1